title: Targeting the immune system to treat hypertension: where are we?
abstract: OBJECTIVE
  Research over the past decade has significantly deepened our understanding of mechanisms that drive the development of hypertension. In particular, a novel paradigm of inflammation as a common mediator of cardiovascular and kidney disease has emerged. This review will summarize the role of the immune system in cardiovascular disease, explore some of the most promising new therapeutic directions and consider their potential as new treatments for hypertension.
  
  
  RESULTS
  Recent data continue to demonstrate that targeting the immune system can prevent hypertension in a variety of experimental models. Tempering the enthusiasm for a long-awaited new approach to treating hypertension is decades of clinical data, showing that classic immunosuppression regimens are associated with significant side-effects - including cardiovascular disease - that effectively preclude their use in the setting of chronic hypertension. New, more specific therapies are being developed that target cytokines including IL-17, IL-6 and TNFα.
  
  
  CONCLUSIONS
  Preclinical data convincingly demonstrate a key role for the immune system and specific cytokine mediators. Several biotherapeutics targeting these pathways are on the market and more are in development. Side-effects, however, continue to resemble those of classic immunosuppressants, highlighting the challenge of translating these research advances into new therapies for hypertension.
  http://links.lww.com/CONH/A9.
authors.affiliation: Department of Pharmaceutical Sciences, Philadelphia College of Osteopathic Medicine, School of Pharmacy, Suwanee, Georgia, USA.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Gooch
authors.forename: Avadhesh C
authors.initials: AC
authors.lastname: Sharma
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D016207:Cytokines / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D007107:Immune System / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D016207:Cytokines; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators